While the patentability of further medical use claim defined by a dosage regimen used to be ruled out, the EPO's Enlarged Board of Appeal has accepted them since decision G 2/08 in 2010. This…
Reading the title of this paper, perhaps you will smile, thinking about all the discussions that this issue has already ignited, even before the UPC came into force. Since the beginning, most…
The question of the role that UPC is likely to play in relation to SEPs (and therefore FRAND licenses) is one that I've heard most often since the new jurisdiction was born, certainly because the…
This week we reported on the case between Huawei and Netgear, in which the defendant had obtained a production order for a comparable license granted by Huawei to Qualcomm, the production of which…
Like a time machine, we began yesterday by examining the first revocation decision issued by the Munich Central Division on 16 July (see here), today we’ll be looking back at another earlier case, in…
On 16 July 2024, the Munich Central Division revoked a patent for the first time in the litigation between Sanofi, Regeneron, and Amgen (UPC_CFI_1/2023). This decision is important not only because…
Regular readers of this blog will be aware of my interest, or rather my passion, for several Patent Law topics, including notably SEPs (see notably here, here and here), proof of infringement (see…
Just over a year after the UPC Agreement came into force, the Paris local division handed down UPC's first decision on an infringement action. Unfortunately for the patentee, the court dismissed his…
Readers are familiar with the story of the founding of the UPC, which “obliged” its founders to make it an ad hoc Court, not integrated into the European judicial system (with a reinforced…
